New aspects of photodynamic therapy for central type early stage lung cancer

Ikeda, Norihiko; Usuda, Jitsuo; Kato, Harubumi; Ishizumi, Taichiro; Ichinose, Shuji; Otani, Keishi; Honda, Hiroaki; Furukawa, Kinya; Okunaka, Tetsuya; Tsutsui, Hidemitsu

doi:10.1002/lsm.21091

Cited by 56 publications

(23 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although using autofluorescence bronchoscopy to determine the superficial extent of lesions was a strength of our study, we didn’t have radial balloon probe EBUS for the first 15 cases, which would have otherwise enhanced the precision of lesion assessment. PDT studies using porfimer sodium have suggested that treating CIS/MIC lesions with longitudinal length >1 cm had less chance of CR as they tend to have deeper invasion 5, 6 . This perception of lack of efficacy of PDT of CIS/MIC >1 cm and cartilage invasion may however not be true for all PS agents.…”

Section: Discussionmentioning

confidence: 99%

A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non–Small Cell Carcinoma In Situ or Non–Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study

Dhillon

Demmy

Yendamuri

et al. 2016

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction We report a phase I trial of photodynamic therapy (PDT) of carcinoma-insitu (CIS) and microinvasive cancer (MIC) of the central airways with the photosensitizer (PS) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH). HPPH has the advantage of minimal general phototoxicity over the commonly used PS porfimer sodium (Photofrin®). Methods The objectives of this study were 1) to determine the maximally tolerated light dose at a fixed PS dose and 2) to gain initial insight into the effectiveness of this treatment approach. Seventeen patients with 21 CIS/MIC lesions were treated with HPPH with light dose escalation starting from 75 J/cm2 to 85, 95,125, and 150 J/cm2 respectively. Follow-up bronchoscopy for response assessment was done at one and six months, respectively. Results The rate of pathological complete response (CR) was 82.4% (14/17 evaluable lesions; 14 patients) at one-month and 72.7% (8/11 lesions; 8 patients) at 6 months. Only 4 patients developed mild skin erythema. One of the three patients in 150 J/cm2 light dose group experienced a serious adverse event. This patient had respiratory distress due to mucus plugging, which precipitated cardiac ischemia. Two additional patients treated subsequently at this light dose had no adverse events. The third sixth patient in this dose group was not recruited and the study was terminated because of delays in HPPH supply. However, given the observed serious adverse event, it is recommended that the light dose not exceed 125J/cm2. Conclusions PDT with HPPH can be safely used for the treatment of CIS/MIC of the airways, with potential effectiveness comparable to that reported for porfimer sodium in earlier studies.

show abstract

Section: Discussionmentioning

confidence: 99%

A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non–Small Cell Carcinoma In Situ or Non–Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study

Dhillon

Demmy

Yendamuri

et al. 2016

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…For endotracheal CTLC, many thermal ablation approaches have been developed to relieve the distressing breathlessness, cough and obstructive pneumonia and improve respiratory function and performance status, including photodynamic therapy [7,26], brachytherapy [20,21], laser therapy [6], airway stenting [22] and endobronchial cryosurgery [15]. Among patients with extratracheal CTLC, only a minority are candidates for surgery [12,16,30], and chemotherapy and external beam radiation therapy have not greatly affected patient outcomes [5,23].…”

Section: Discussionmentioning

confidence: 99%

Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients

Zhang¹,

Niu²,

Liang³

et al. 2013

Cryobiology

View full text Add to dashboard Cite

“…Mucosal ablation techniques using lasers are currently being widely and successfully used for the treatment of superficial gastrointestinal cancers including early gastric cancer, superficial esophageal cancer, colorectal adenoma, and high-grade Barrett's esophagus (24). Moreover, photodynamic therapy (PDT) using lasers has also been shown to be an effective treatment modality for specific types of lung cancer lesions (25).…”

Section: Oncologymentioning

confidence: 99%

Laser applications in surgery

Azadgoli¹,

Baker²

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

In modern medicine, lasers are increasingly utilized for treatment of a variety of pathologies as interest in less invasive treatment modalities intensifies. The physics behind lasers allows the same basic principles to be applied to a multitude of tissue types using slight modifications of the system. Multiple laser systems have been studied within each field of medicine. The term "laser" was combined with "surgery," "ablation," "lithotripsy," "cancer treatment," "tumor ablation," "dermatology," "skin rejuvenation," "lipolysis," "cardiology," "atrial fibrillation (AF)," and "epilepsy" during separate searches in the PubMed database. Original articles that studied the application of laser energy for these conditions were reviewed and included. A review of laser therapy is presented.Laser energy can be safely and effectively used for lithotripsy, for the treatment of various types of cancer, for a multitude of cosmetic and reconstructive procedures, and for the ablation of abnormal conductive pathways. For each of these conditions, management with lasers is comparable to, and potentially superior to, management with more traditional methods.

show abstract

New aspects of photodynamic therapy for central type early stage lung cancer

Abstract: The present guidelines of PDT for CELC were established based on the data obtained from studies in the 1980's. We postulate that comprehensive diagnosis and the new generation of photosensitizers may increase the CR rate and expand the indications of PDT for larger tumors.

Cited by 56 publications

References 38 publications

A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non–Small Cell Carcinoma In Situ or Non–Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study

A Phase I Study of Light Dose for Photodynamic Therapy Using 2-[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a for the Treatment of Non–Small Cell Carcinoma In Situ or Non–Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study

Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients

Laser applications in surgery

Contact Info

Product

Resources

About